Abstract: Antigen binding proteins that bind ?-amyloid peptide, in particular human ?-amyloid peptide; methods of treating diseases or disorders characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, including age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with the antigen binding proteins; pharmaceutical compositions comprising the antigen binding proteins; and methods of manufacture.

Abstract: The invention relates to combinations of TNF? antagonists with VEGF antagonists for use in treating diseases of the eye, and provides antigen-binding proteins which bind to TNF? or a TNF? receptor and/or VEGF or a VEGF receptor.

Abstract: The invention relates to combinations of FGFR1c antagonists with agonist peptides and provide dual targeting proteins which bind to FEFR1c comprising an antigen binding protein which is capable of binding to FGFR1c and which is linked to one or more agonist peptides, methods of making such constructs and uses thereof, particularly in treating obesity.

Abstract: The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles using Hip agents. Also provided are compositions comprising particulate carriers obtainable by such methods and uses of such compositions in treatment.

Abstract: The present invention provides methods of encapsulating biologically active agents such as proteins in particulate carriers such as nanoparticles. Also provided are methods of delivery of proteins across the blood brain barrier in nanoparticles, and uses of such compositions in treatment.

Abstract: Antigen binding proteins that bind ?-amyloid peptide, in particular human ?-amyloid peptide; methods of treating diseases or disorders characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterised by elevated ?-amyloid levels or ?-amyloid deposits, including age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with said antigen binding proteins; pharmaceutical compositions comprising said antigen binding proteins; and methods of manufacture.

Abstract: The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment thereof and RT or a fragment thereof.

Abstract: The present invention provides a novel polynucleotide vectors and their use in the production of biological material in host cells, and also in medical therapy or polynucleotide vaccination. The novel vectors of the present invention comprise a promoter normally associated with the US3 gene of Human Cytomegalovirus (HCMV).

Abstract: The present invention relates to methods and compositions useful in the treatment and prevention of human papilloma virus infections and the symptoms and diseases associated therewith. More particularly, the invention relates to polynucleotide sequences which encode human papilloma virus (HPV) amino acid amino acid sequences, wherein the codon usage pattern of the polynucleotide sequences resemble those of highly expressed mammalian genes.